Mentions of virtual care decreased in the pharmaceutical industry in Q1 2023

Notably, virtual care was one of the most frequently referenced themes in Q1 2023, ranking highest in terms of mentions, ahead of customer loyalty and cloud, according to GlobalData.

Of the top leading companies in the pharmaceutical industry, ICON had the greatest increase in references for virtual care in Q1 2023, compared with the previous quarter. GlobalData identified 9 virtual care-related sentences in the company’s filings – 0.3% of all sentences – and an increase of 100% in Q1 2023 compared with Q1 2022. Neurocrine Biosciences’s mentions of virtual care rose by 100% to 3 and UCB’s by 100% to 2 and F. Hoffmann-La Roche’s by 100% to 1 and Pfizer’s by 100% to 1.

GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for virtual care in Q1 2023 was 60.

For further understanding of GlobalData’s Telehealth Market Size by Segments, Share, Trends, and Forecast, 2022-2030 buy the report here.

Subscribe to our Newsletter

Get industry leading news, data and analysis delivered to your inbox

Subscribe

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Company Filings Analytics uses machine learning to uncover key insights and track sentiment across millions of regulatory filings and other corporate disclosures for thousands of companies across the world’s largest industries.